Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market to Reach $4.4 Billion by 2030
The global market for Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs estimated at US$3.6 Billion in the year 2023, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2023-2030. Lipopeptide Drugs, one of the segments analyzed in the report, is expected to record a 3% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Oxazolidinone Drugs segment is estimated at 3.1% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 3.1% CAGR
The Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$791.7 Million by the year 2030 trailing a CAGR of 3.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 2.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook